Phuturdex › Diseases › Atherosclerosis
Drugs in development · updated 30 October 2026
Atherosclerosis: drugs in development
As of 30 October 2026 there are 43 active clinical trials (recruiting or ongoing, phases I–III) on 34 drugs for atherosclerosis. 25 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AZD0780 | III | 2 | NCT07000357 |
| CSL300 | II–III | 2 | NCT05485961 |
| Lepodisiran | III | 2 | NCT07613294 |
| Pelacarsen | III | 2 | NCT06813911 |
| Ziltivekimab | III | 2 | NCT06263244 |
| Anacetrapib | III | 1 | NCT01252953 |
| HRS9531 | III | 1 | NCT07551492 |
| Maridebart cafraglutide | III | 1 | NCT07037433 |
| Muvalaplin | III | 1 | NCT07157774 |
| Nicorandil Oral Tablet | III | 1 | NCT07800351 |
| ObicetrapibUbeslo® | III | 1 | NCT05202509 |
| Olpasiran | III | 1 | NCT05581303 |
| Retatrutide | III | 1 | NCT06383390 |
| YN001 | II | 2 | NCT07521007 |
| Clazakizumab | II | 1 | NCT07783802 |
| DII235 | II | 1 | NCT07235046 |
| Glucose20% D-glucose | II | 1 | NCT07311330 |
| SAL0137 | II | 1 | NCT07729475 |
| Selnoflast | II | 1 | NCT07448038 |
| TB-500 | I–II | 1 | NCT07487363 |
| Tertinat | II | 1 | NCT06590012 |
| VERVE-102 | II | 1 | NCT07839936 |
| STX-1150 | I | 1 | NCT07428473 |
| IMC-001 | Early I | 1 | NCT06788431 |
| UDP-003 | Early I | 1 | NCT06813339 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ColchicineColchicin, Lodoco® | III | 6 | NCT06930885 |
| InclisiranLeqvio® | III | 4 | NCT06813911 |
| AspirinVazalore®, Durlaza® | III | 2 | NCT06930885 |
| MetforminRiomet Er®, Glumetza® | III | 2 | NCT05132439 |
| AtorvastatinLipitor, Atorvaliq® | III | 1 | NCT06930885 |
| TicagrelorBrilinta®, Brilique® | III | 1 | NCT05476991 |
| Bempedoic acidNexletol®, Nilemdo® | II | 1 | NCT05488431 |
| PitavastatinNikita®, Zypitamag® | II | 1 | NCT07460960 |
| RosuvastatinEzallor Sprinkle®, Crestor® | II | 1 | NCT07460960 |
Sorted by most advanced phase and number of active trials.
All 34 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Peripheral Arterial Disease 25 drugs
- Peripheral vascular disease 7 drugs
- Chronic Limb-Threatening Ischemia 5 drugs
- Intermittent claudication 7 drugs
- Chronic arterial occlusive disease 3 drugs
- Ischemia 5 drugs
- Inflammation 85 drugs
- Myocardial infarction 26 drugs
- Stroke 70 drugs
- Thrombosis 19 drugs
- Acute coronary syndrome 17 drugs
- Diabetes 91 drugs
Broader categories
- Chronic arterial occlusive disease 3 drugs
- Vascular disease 16 drugs
- Cardiovascular disease 71 drugs
- Nutritional and metabolic diseases 5 drugs
- Myocardial ischemia 6 drugs
- Metabolic disease 30 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D050197 “Atherosclerosis”.